GHO and CBC Forge $21B Global Healthcare Investment Superpower

London & Singapore – May 20, 2026 – In a landmark transaction poised to reshape the global healthcare investment landscape, European specialist GHO Capital and Asian asset manager CBC Group today announced a definitive agreement to merge. The combination will create the world’s largest dedicated healthcare investment firm, managing over $21 billion in assets and uniting two powerhouses from opposite ends of the globe.

The new entity brings together GHO’s deep European and North American networks with CBC Group’s dominant presence in Asia’s burgeoning healthcare market. With a combined force of over 200 professionals across 13 offices, the firm will have a strategic foothold in regions that collectively account for 90% of global healthcare research and development spending. The leadership will be shared, with GHO Co-founder Mike Mortimer and CBC Founder Fu Wei serving as Co-Chief Executives. Fu Wei will also co-chair the board alongside GHO’s Vice Chair and Co-founder, Lady Mireille Gillings.

A New Colossus in Healthcare Private Equity

The sheer scale of this merger creates a new heavyweight champion in the specialized investment arena. With over $21 billion in assets under management (AUM), the combined firm not only becomes the largest dedicated healthcare investor but also a formidable competitor to the healthcare divisions of global private equity giants like Blackstone, KKR, and Carlyle Group. This move signals a significant consolidation trend within the highly specialized and lucrative healthcare sector, where scale, global reach, and deep operational expertise are increasingly critical for success.

The firm's expansive footprint is a core component of its strategy. By establishing a presence across North America, Europe, and Asia-Pacific, it aims to capture growth and innovation wherever they arise. This global network will provide an unparalleled platform for its portfolio companies, which span pharmaceuticals, medical devices, diagnostics, and healthcare IT.

"By uniting our collective regional expertise, capabilities and shared commitment to identifying and growing leading healthcare companies, we are positioning ourselves to achieve strong returns, as well as further deliver on our commitment to improving global health outcomes,” said Mike Mortimer, Managing Partner and Co-Founder of GHO Capital, in the official announcement. The firm will be uniquely positioned to offer investors a diverse array of opportunities, including private equity, private credit, and real estate assets, all focused on the resilient and high-growth healthcare and life sciences sectors.

Bridging Continents to Fuel Innovation

At its core, the merger is a strategic play to bridge the world's largest and most innovative healthcare markets. The combination of GHO’s transatlantic expertise and CBC’s deep roots in Asia is designed to create a powerful synergy, accelerating the internationalization of healthcare solutions and connecting capital with cutting-edge science on a global scale.

For GHO’s portfolio of North American and European companies, the merger provides a direct and supported pathway into the dynamic Asia-Pacific region, a key growth frontier. Simultaneously, CBC’s portfolio of Asian healthcare innovators will gain access to GHO’s established networks and operational capabilities in the West, enabling them to scale with confidence. This two-way street of market access is central to the deal's value proposition.

“The combination is about connecting leading healthcare companies and innovations with the world’s largest and most established markets and global pools of capital—by bringing together complementary strengths across Asia-Pacific, North America and Europe,” said Fu Wei, Chief Executive Officer and Founder of CBC Group. This vision is underpinned by the "investor-operator" model that both firms champion, which emphasizes hands-on operational support and strategic guidance beyond mere financial investment.

Navigating a Complex Global Integration

While the strategic rationale is compelling, the execution of such a large-scale, cross-border merger presents significant complexities. The transaction, expected to close in early 2027, is subject to customary closing conditions and a battery of regulatory approvals from antitrust authorities in the United States, Europe, and China, among other jurisdictions. The nearly two-year timeline until closing reflects the intricate legal and regulatory landscape the firms must navigate. Until then, both GHO and CBC will continue to operate independently, ensuring continuity for their respective funds and portfolio companies.

Beyond regulatory hurdles lies the challenge of cultural integration. Merging a European-centric firm with an Asian powerhouse requires a delicate and deliberate approach. The announced leadership structure, featuring co-CEOs and co-chairs from both legacy firms, suggests a commitment to a partnership of equals rather than a takeover. Senior leadership teams from both GHO and CBC are slated to remain actively involved, a move likely intended to retain key talent and ensure a smooth transition. The firms have publicly emphasized their shared "strong entrepreneurial, founder-driven culture," which they believe will serve as a unifying foundation for the combined entity.

Betting on the Future: AI and the Next Wave of Healthcare

Looking ahead, the new firm has clearly signaled its intention to be at the forefront of technological innovation, with a particular focus on artificial intelligence. This strategic priority was underscored by Lady Mireille Gillings, who stated, “AI is a fast-evolving force in healthcare and life sciences, and so AI applications in these fields will continue to be a focus moving forward.”

This focus is not merely aspirational. GHO has already made inroads in this area, notably through its acquisition of Scientist.com, an AI-powered platform for orchestrating research and development. The merger will provide the capital and global platform to double down on this strategy, seeking out and nurturing companies that are leveraging AI to revolutionize drug discovery, create more accurate diagnostics, enable personalized medicine, and streamline healthcare operations.

By embedding AI as a core pillar of its investment thesis, the newly formed entity is positioning itself to capitalize on the profound digital transformation sweeping the healthcare industry. This forward-looking approach aligns with the firm's stated mission to deliver "better, faster and more accessible healthcare globally," suggesting that its immense financial power will be directed not just at scaling existing models but at funding the next generation of medical breakthroughs. The combination of global reach, deep operational expertise, and a strategic focus on advanced technology sets the stage for this new powerhouse to play a pivotal role in shaping the future of health.